• 제목/요약/키워드: Metastatic gastric cancer

검색결과 164건 처리시간 0.027초

Late Stage and Grave Prognosis of Esophageal Cancer in Thailand

  • Nun-anan, Pongjarat;Vilaichone, Ratha-korn
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권5호
    • /
    • pp.1747-1749
    • /
    • 2015
  • Background: Esophageal cancer is one of the major health concerns in Southeast Asian countries, including Thailand. However, only a limited number of studies have been reported from this region. This study was designed to evaluate the prevalence, clinical characteristics and survival rate of esophageal cancer in Thailand. Materials and Methods: Clinical information, histological features and endoscopic findings were collected from a tertiary care center in central region of Thailand between September 2011- November 2014 and reviewed. Results: A total of 64 esophageal cancer patients including 58 men and 6 women with mean age of 62.6 years were enrolled. Common presenting symptoms were dysphagia (74%), dyspepsia (10%) and hematemesis (8%). Mean duration of symptoms prior to diagnosis was 72 days. Esophageal stenosis with contact bleeding was the most common endoscopic finding (55.6%). The location of cancer was found in proximal (16%), middle (50%) and distal (34%) esophagus. Squamous cell carcinoma was far more common histology than adenocarcinoma (84.2% vs 10.5%). However, esophageal adenocarcinoma was significantly more common than squamous cell carcinoma in distal area of esophagus (100% vs 22.9%; p=0.0001, OR=1.6, 95%CI=1.1-2.2). Esophageal cancer stages 3 and 4 accounted for 35.2% and 59.3% respectively. Overall 2-year survival rate was 20% and only 16% in metastatic patients. Conclusions: Most esophageal cancer patients in Thailand have squamous cell carcinoma and nearly all present at advanced stage with a grave prognosis. Screening of high risk individuals and early detection might be important keys to improve the survival rate and treatment outcome in Thailand.

위암에서 조직학적 특징에 따른 혈청 E-cadherin의 농도 (Concentration of E-cadherin Correlated with Pathologic Features in Gastric Cancer)

  • 허훈;송교영;김진조;진형민;김욱;박조현;박승만;임근우;박우배;김승남;전해명
    • Journal of Gastric Cancer
    • /
    • 제4권3호
    • /
    • pp.156-163
    • /
    • 2004
  • Purpose: While E-cadherin in normal cells induces calciumdependent cell-cell adhesion, in malignant cell, it plays a role in invasion and metastasis with a reduction of adhesion. Serum soluble E-cadherin is a result of the reduction of the cellular E-cadherin molecule and is found in the circulation of normal individuals, but it is particularly known to be increased in patients with malignancies. Accordingly, through checking the level of serum soluble E-cadherin in patients with gastric cancer and analyzing it in the view of clinicopathology, we investigated whether serum soluble E-cadherin could be translated into a clinicopathologic esult and used as a tumor marker. Materials and Methods: The investigation targeted 88 patients who had been diagnosed as having gastric cancer by the Department of Surgery, St. Mary's Hospital, from October 1, 2002, to July 30, 2003, and who had under gone performed surgery. We measured the level of preoperative serum E-cadherin in the 88 patients by unsing ELISA. Among them, we collected gastric cancer tissues from 54 patients and executed immunohistochemistry for E-cadherin. The samples were compared with normal tissues in terms of both serum E-cadherin level and immunohistochemistry level, as well as with other clinicopathologic factors. Result: The mean serum E-cadherin level of the 88 patients was 4368.7 ng/ml and was significantly higher than the level in 12 normal control patients, 3335.5 ng/ml (P=0.016). In terms of clinicopathology, the serum level of E-cadherin was significantly correlated with increasing age (P=0.0006) and was higher in positive venous invasion patients (P=0.0005). When the E-cadherin immunohistochemical stain was compared with the serum E-cadherin level in 54 patients, no significant statistically meaningful result was obtained (P=0.2881). However, 4 patients with serum E-cadherin levels about 6000 ng/ml were classified into the lower expression group ($<80\%$ of E-cadherin immunohistochemicals stain. In the analysis for 36 patients who were early gastric cancer patients, the serum E-cadherin level in lymph-node-metastatic patients was higher than it was in the other patients (P=0.0442). Conclusion: The serum E-cadherin level in gastric cancer patients was higher than the level in normal control patients. In advanced gastric cancer patients, that the difference was increased. Also, since the E-cadherin level correlated with the serum E-cadherin level with venous invasion, it can be used as an effective tumor marker for gastric cancer. Particularly, in that the serum E-cadherin level correlated with lymph node metastasis in early gastic cancer, it can be used when a therapeutic method for early gastric cancer is selected.

  • PDF

다발성 전이가 동반된 위암 환자에서 Trastuzumab 치료로 부분 관해를 보인 1례 (A Case of Partial Response with Trastuzumab Based Treatment in Advanced Gastric Cancer with Multiple Metastasis)

  • 이서희;정현용;문희석;성재규;강선형;김주석
    • Journal of Digestive Cancer Research
    • /
    • 제5권2호
    • /
    • pp.125-129
    • /
    • 2017
  • ToGA 연구 결과를 바탕으로 하여, HER2 강양성을 보이는 진행성 위암의 경우에는 Trastuzumab을 기존의 항암제에 병합하여 치료하였을 때 더 좋은 반응과 생존율 향상을 기대할 수 있겠다. 이에 저자들은 HER2 강양성을 보이는 간과 폐와 림프절 전이 등 다발성 전이가 있는 진행성 위암 환자에서 Trastuzumab과 5-Fluorouracil (5-FU)과 Cisplatin 병합 항암요법을 함께 사용하여 큰 부작용 없이 간과 폐, 림프절에 다발성 전이 병변들의 크기가 감소하여 부분 관해를 보인 환자의 증례를 문헌고찰과 함께 보고하는 바이다.

  • PDF

내시경점막하박리술의 적응증을 넘어선 조기위암의 미세침습 치료 후 장기 추적 결과 (Long-term Outcome after Minimally Invasive Treatment for Early Gastric Cancer beyond the Indication of Endoscopic Submucosal Dissection)

  • 고원진;조주영
    • Journal of Digestive Cancer Research
    • /
    • 제5권1호
    • /
    • pp.44-49
    • /
    • 2017
  • Background: 최근 제안된 조기위암에 대한 미세침습 치료법은 내시경점막하박리술(endoscopic submucosal dissection, ESD)혹은 종양 부위를 전층 절제(endoscopic full-thickness gastric resection, EFTGR)을 통해 위 절제를 최소화하고 동시에 복강경을 통해 감시림프절 절제(sentinel lymph node dissection, SLND)를 시행함으로써 그 가능성을 제시했었고, 이들을 각각 ESN (endoscopic submucosal dissection with laparoscopic sentinel lymph node dissection), Hybrid-NOTES (endoscopic full-thickness gastric resection with laparoscopic sentinel lymph node dissection)라고 명명하였다. 본 고에서는 림프절 전이 위험성이 높은 조기위암에 대해 이 두 치료법을 시행받은 환자들의 장기 추적 결과를 평가하고자 한다. Methods: 이 후향적 연구는 2009년 1월부터 2013년 5월 중에 ESN 혹은 Hybrid-NOTES를 시행받은 환자들이 포함되었다. Results: 총 42명의 환자들이 연구에 포함되었고, ESN 21명, Hybrid-NOTES 21명이 각각 등록되었다. ESN을 시행받은 21명 중 4명, Hybrid-NOTES를 시행받은 5명은 이 미세침습수술 후 추가 수술을 받아야 했다. 아직까지 이 수술 후 사망 환자는 없지만 ESN을 시행받은 1명의 환자에서 림프절 전이가 발견되어 항암치료를 받고 있다. Conclusion: 조기위암의 미세침습 수술인 ESN 혹은 Hybrid-NOTES는 좋은 장기 추적 결과를 보여주었다. 이 방법들은 향후 림프절 전이 위험성이 높은 조기위암에서 ESD와 gastrectomy 사이에 속한 환자들에게 좋은 치료법이 될 수 있을 거라고 생각된다.

  • PDF

난치성 복막암종증의 치료 전략에 대한 고찰 (Treatment Strategy of Intractable Peritoneal Carcinomatosis)

  • 정재규;임윤정
    • Journal of Digestive Cancer Research
    • /
    • 제1권1호
    • /
    • pp.29-35
    • /
    • 2013
  • 복막암종증(Peritoneal carcinomatosis)은 복강내에 암세포가 파종되어 벽쪽 복막과 내장쪽 복막 표면에 악성세포가 축적되는 상태로 정의할 수 있으며, 이것은 암성복수와도 관련 있다. 일반적으로 복막암종증은 원발암의 전이성 암과 유사하게 치료하나 같은 원발암의 다른 장기로의 전이암과는 달리 예후가 좋지 않다. 보존적 치료만 했을 경우 복막암종증 환자의 중앙생존기간은 3-6개월이다. 복막암종증은 예후가 좋지 않고 치료 방법이 제한적이어서 일선에서 치료하는 내과 의사에겐 여전히 어려운 과제이기도 하다. 최근에 이와 관련된 치료 방법이 많이 연구되어 육안적 병소제거술 및 복막절제술(cytoreductive surgery with peritonectomy)과 함께 조기 수술 후 복강내 화학요법(early postoperative intraperitoneal chemotherapy, EPIC) 또는 수술 중 복강내 온열화학요법(hyperthermic intraperitoneal chemotherapy, HIPEC)을 시행하여 생존율을 향상시키고 있다. 본 논문에서는 복막암종증의 전반적인 특징, 증상, 예후 및 진단과 수술적 방법, 항암 화학요법 등의 치료법에 대하여 알아보고자 한다.

  • PDF

Clinicopathologic characteristics and survival rate in patients with synchronous or metachronous double primary colorectal and gastric cancer

  • Park, Ji-Hyeon;Baek, Jeong-Heum;Yang, Jun-Young;Lee, Won-Suk;Lee, Woon-Kee
    • 대한종양외과학회지
    • /
    • 제14권2호
    • /
    • pp.83-88
    • /
    • 2018
  • Purpose: Double primary colorectal cancer (CRC) and gastric cancer (GC) represent the most common multiple primary malignant tumors (MPMT) in Korea. The recognition and screening of hidden malignancies other than the primary cancer are critical. This study aimed to investigate the clinicopathologic characteristics and survival rates in patients with synchronous or metachronous double primary CRC and GC. Methods: Between January 1994 and May 2018, 11,050 patients were diagnosed with CRC (n=5,454) or GC (n=5,596) at Gil Medical Center. MPMT and metastatic malignant tumors were excluded from this study. A total of 103 patients with double primary CRC and GC were divided into two groups: the synchronous group (n=40) and the metachronous group (n=63). The incidence, clinicopathologic characteristics, and survival rate of the two groups were analyzed. Results: The incidence of synchronous and metachronous double primary CRC and GC was 0.93%. Double primary CRC and GC commonly occurred in male patients aged over 60 years with low comorbidities and minimal previous cancer history. There were significant differences between the synchronous and metachronous groups in terms of age, morbidity, and overall survival. Metachronous group patients were 6 years younger on average (P=0.009), had low comorbidities (P=0.008), and showed a higher 5-year overall survival rate (94.8% and 61.3%, P<0.001) in contrast to synchronous group. Conclusion: When primary cancer (CRC or GC) is detected, it is important to be aware of the possibility of the second primary cancer (GC or CRC) development at that time or during follow-up to achieve early detection and better prognosis.

Preoperative N Staging of Gastric Cancer by Stomach Protocol Computed Tomography

  • Kim, Se Hoon;Kim, Jeong Jae;Lee, Jeong Sub;Kim, Seung Hyoung;Kim, Bong Soo;Maeng, Young Hee;Hyun, Chang Lim;Kim, Min Jeong;Jeong, In Ho
    • Journal of Gastric Cancer
    • /
    • 제13권3호
    • /
    • pp.149-156
    • /
    • 2013
  • Purpose: Clinical stage of gastric cancer is currently assessed by computed tomography. Accurate clinical staging is important for the tailoring of therapy. This study evaluated the accuracy of clinical N staging using stomach protocol computed tomography. Materials and Methods: Between March 2004 and November 2012, 171 patients with gastric cancer underwent preoperative stomach protocol computed tomography (Jeju National University Hospital; Jeju, Korea). Their demographic and clinical characteristics were reviewed retrospectively. Two radiologists evaluated cN staging using axial and coronal computed tomography images, and cN stage was matched with pathologic results. The diagnostic accuracy of stomach protocol computed tomography for clinical N staging and clinical characteristics associated with diagnostic accuracy were evaluated. Results: The overall accuracy of stomach protocol computed tomography for cN staging was 63.2%. Computed tomography images of slice thickness 3.0 mm had a sensitivity of 60.0%; a specificity of 89.6%; an accuracy of 78.4%; and a positive predictive value of 78.0% in detecting lymph node metastases. Underestimation of cN stage was associated with larger tumor size (P<0.001), undifferentiated type (P=0.003), diffuse type (P=0.020), more advanced pathologic stage (P<0.001), and larger numbers of harvested and metastatic lymph nodes (P<0.001 each). Tumor differentiation was an independent factor affecting underestimation by computed tomography (P=0.045). Conclusions: Computed tomography with a size criterion of 8 mm is highly specific but relatively insensitive in detecting nodal metastases. Physicians should keep in mind that computed tomography may not be an appropriate tool to detect nodal metastases for choosing appropriate treatment.

소세포 폐암에서의 위 전이 2예 (Two Cases of Gastric Metastasis from Small Cell Lung Cancer)

  • 유광하;김형중;안철민;이세준;김성규;이원영
    • Tuberculosis and Respiratory Diseases
    • /
    • 제46권2호
    • /
    • pp.273-280
    • /
    • 1999
  • 저자들은 소세포 폐암으로 확진된 환자에서 오심 구토 혈변등 위장관 증상을 호소하여 상부 위 내시경 검사 및 조직 생검을 시행하여 위장으로의 전이를 확인한 2 예를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

  • PDF